09E07A63-5FD2-4E4F-9FD5-2BB204302232
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 135.11826544021025
- age_years
- 34
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.526
- CHOLESTEROL_HOMEOSTASIS+0.456
- MYC_TARGETS_V2+0.452
- NOTCH_SIGNALING+0.449
- UNFOLDED_PROTEIN_RESPONSE+0.439
- DNA_REPAIR+0.417
- OXIDATIVE_PHOSPHORYLATION+0.408
- WNT_BETA_CATENIN_SIGNALING+0.391
- PROTEIN_SECRETION+0.372
- MTORC1_SIGNALING+0.361
Top 10 suppressed
- KRAS_SIGNALING_DN-0.429
- SPERMATOGENESIS-0.289
- COAGULATION-0.262
- ANGIOGENESIS-0.243
- ALLOGRAFT_REJECTION-0.220
- MYOGENESIS-0.207
- INFLAMMATORY_RESPONSE-0.197
- INTERFERON_ALPHA_RESPONSE-0.193
- ESTROGEN_RESPONSE_LATE-0.168
- INTERFERON_GAMMA_RESPONSE-0.164
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 92A04345-2DCA-49F5-801F-926B59255925 | — | — | 0.915 |
| 2 | 53426017-24F2-4348-BEE1-05E80B6A0E6B | — | — | 0.910 |
| 3 | 0093DCB6-A7C8-4841-8383-0671A71DDA71 | — | — | 0.893 |
| 4 | 2482156E-29A8-4B6B-91BD-219EAC9229B5 | — | — | 0.884 |
| 5 | D0F8B6CA-5F3B-4B66-BCC5-72C17325DABF | — | — | 0.880 |
| 6 | BE71F250-1529-43BD-84F3-3AFE1B42D77D | — | — | 0.878 |
| 7 | CD628EE7-84DE-4D82-840B-73718D006B6F | — | — | 0.872 |
| 8 | 68CE8E02-F24A-4580-9881-DFBB288E2ED7 | — | — | 0.871 |
| 9 | 3A2D0D6F-66C3-48EE-9EA4-68668FF9B043 | — | — | 0.871 |
| 10 | 7A392761-6834-4B60-A49A-99D0D2AEC612 | — | — | 0.866 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 32 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.526 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.456 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.452 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.449 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.439 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.417 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.408 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.391 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.372 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.361 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.354 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.312 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.288 | Cobimetinib | — uncovered |
| UV_RESPONSE_UP | 0.253 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.245 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.214 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.211 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.160 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.157 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.121 | Inavolisib | — uncovered |